SCHEMBL194498

SCHEMBL194498

CCN(CC)c1ccc(/C=C2/SC(=S)NC2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 3/20 1.00
CRHR2 Q13324 3/20 1.00
MYC P01106 3/20 0.68
MAX P61244 3/20 0.68
NPC1 O15118 1/20 0.68
RAB9A P51151 1/20 0.68
GSK3B P49841 1/20 0.67
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
POLB P06746 1/20 0.65
GPR35 Q9HC97 1/20 0.65
NAT1 P18440 5/20 0.61
CISD1 Q9NZ45 1/20 0.61
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
GAA P10253 1/20 0.60
MAPT P10636 1/20 0.60
MAPK1 P28482 1/20 0.60
NTSR1 P30989 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249353 1.00 CRHBP (1.00) CRHBPCRHR2MYCMAXNPC1
SCHEMBL194499 1.00 CRHBP (1.00) CRHBPCRHR2MYCMAXNPC1
SCHEMBL14891689 0.95 CRHBP (0.90) CRHBPCRHR2MYCMAXNPC1
SCHEMBL14891688 0.95 CRHBP (0.90) CRHBPCRHR2MYCMAXNPC1
SCHEMBL12218499 0.89 CRHBP (0.81) CRHBPCRHR2MYCMAXNPC1
SCHEMBL4101541 0.88 CRHBP (0.79) CRHBPCRHR2NPC1RAB9AGSK3B
SCHEMBL4101538 0.88 CRHBP (0.79) CRHBPCRHR2NPC1RAB9AGSK3B
SCHEMBL8177383 0.85 CRHBP (0.74) CRHBPCRHR2MYCMAXNPC1
SCHEMBL4100036 0.84 CRHBP (0.73) CRHBPCRHR2NPC1RAB9AGSK3B
SCHEMBL4100041 0.84 CRHBP (0.73) CRHBPCRHR2NPC1RAB9AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 EP claimed
EP-4743828-A1 PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING BASF SE (DE) 2026-05-20 EP disclosed
US-20250149336-A1 PHOTORESIST COMPOSITION AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-05-08 US disclosed
WO-2025011754-A1 PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING BASF SE (DE) 2025-01-16 WO disclosed
EP-4114825-B1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2024-11-20 EP disclosed
WO-2024043108-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED FILM, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND RADICAL POLYMERIZATION INITIATOR 富士フイルム株式会社 2024-02-29 WO disclosed
US-20230142648-A1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2023-05-11 US disclosed
EP-4114825-A1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2023-01-11 EP disclosed
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US disclosed
US-20020020832-A1 Photosensitive resin composition CIBA SPECIALTY CHEMICALS CORP. 2002-02-21 US disclosed
EP-1163553-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS Ciba SC Holding AG (CH) 2001-12-19 EP disclosed
US-20010012596-A1 For resist applications; thermostability, storage stability CIBA SPECIALTY CHEMICALS CORP. 2001-08-09 US disclosed
WO-2000052530-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-09-08 WO disclosed
EP-0733649-B1 Peroxycarboxylic ester photoinitiators derived from nitrogen heterocycles MINNESOTA MINING & MFG (US) 2000-07-12 EP disclosed
US-5693442-A ELEMENT HAVING OVERCOAT OVERLYING CHARGE GENERATING LAYER COMPRISING DYE AND/OR ORGANIC PIGMENT AND COMPLEX OF INORGANIC OXIDE POLYMER AND CHARGE CARRIER EASTMAN KODAK COMPANY (US) 1997-12-02 US disclosed
US-5599652-A PHOTOPOLYMERIZABLE MIXTURES ALSO WITH FREE RADICAL POLYMERIZABLE COMPOUNDS AND PHOTOSENSITIZERS IMATION CORP. (US) 1997-02-04 US disclosed
EP-0733649-A1 Peroxycarboxylic ester initiators derived from nitrogen heterocycles MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-09-25 EP disclosed
US-5527921-A USEFUL IN PHOTOPOLYMERIZABLE COMPOSITIONS AND PHOTOSENSITIVE ELEMENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142648-A1 OXIME ESTER PHOTOINITIATORS OCIAD1, OCIAD2, OXER1 CRHBP 3062/4885CRHR2 3308/4885MYC 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.